Menu

Recent Interviews

Alex Kent, Managing Director, Aspermont Limited

Alex Kent
Managing Director | Aspermont Limited
613 - 619 Wellington Street, WA, 6000 Perth (AUS)

Corporate@aspermont.com

+61 8 6263 9100

Aspermont shows the success of digitalization - Alex Kent has an agenda


Jim Payne, CEO, dynaCERT Inc.

Jim Payne
CEO | dynaCERT Inc.
101-501 Alliance Avenue, M6N 2J1 Toronto, Ontario (CAN)

jpayne@dynacert.com

+1 416 766 9691

dynaCERT CEO Jim Payne on attractive hydrogen opportunities


Sebastian-Justus Schmidt, CEO and Founder, Enapter AG

Sebastian-Justus Schmidt
CEO and Founder | Enapter AG
Ziegelhäuser Landstraße 1, 69120 Heidelberg (D)

info@enapterag.de

Enapter AG CEO and founder Sebastian-Justus Schmidt on the future of hydrogen


16. April 2020 | 07:55 CET

Johnson & Johnson, Memphasys, Procter & Gamble - for a better life

  • Health
Photo credits: pixabay.com

Good health is a valuable possession. Small and large companies around the globe are engaged in research and development to make people's lives easier or better through modern and innovative products and solutions. The consumer goods and pharmaceutical sectors often offer attractive opportunities for investors to generate a lucrative return. Well-known companies with established brands usually ensure lasting sales. However, promising young companies also use innovations to attract the attention of investors and customers.

time to read: 1 minutes by Mario Hose


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


Innovation helps with the desire for children

Memphasys from Australia deals with the subject of in-vitro fertilization. The target groups are couples who wish to have children but have not yet been able to achieve a successful pregnancy by natural means. The company has developed a product called FELIX, which is used in the field of bio-separation of sperm. With this innovation, the particularly promising sperm cells are separated from the seminal fluid in just a few minutes to increase the chances of a successful pregnancy. Initially, the focus is on artificial insemination of humans, but in the future animals will also be accompanied.

Alison Coutts is Executive Chairman of Memphasys and explains the product and future areas of application in a video - youtu.be/kHA-UhbeZH8. FELIX is expected to be launched in the second half of 2020. The company currently has a market capitalization of around AUD 35 million and a successful market launch offers corresponding potential for the shares.

Group with brands

Johnson & Johnson is a broad-based group from the USA and is a member of the Dow Jones Index. The market value of the company is around USD 390 billion. Johnson & Johnson products are available under various brands worldwide and can be found in virtually every household. The pharmaceutical and consumer goods manufacturer has a highly diversified product universe and can therefore benefit from a variety of revenue streams. Optimal conditions for conservative investors.

Dividend stock with consumer goods

Procter & Gamble is also a member of the Dow Jones Index and has a market capitalization of approximately USD 300 billion. The manufacturer of consumer goods can also offer a wide range of products from around the world on the shelves of drugstores and supermarkets. The company aims to improve the lives of its customers with products in the Care, Hygiene, Healthcare and Household segments. Due to the size of the company and the diversity of its product range, the dividend stock can build on numerous revenue streams and drive development.


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

23. December 2020 | 08:50 CET | by André Will-Laudien

Q & M Dental, Moderna, AstraZeneca: Serving people!

  • Health

Rarely has the stock market been so focused on people as it has been during the pandemic. People are thinking about which companies offer the best service package for all the problems associated with infections, vaccinations and even the psychological effects of isolation and loneliness. Humans are "social animals" with multiple social needs. Curtailing these needs works temporarily, but at some point, the arguments have to be genuinely purposeful so that certain restrictions continue to be accepted. At the peak of the contagion curve, we would like to see possible remedies that quickly turn the overall situation into a positive end - this is possible for the medium-term future. Still, in the short term, we have to stick together.

Read

27. October 2020 | 10:17 CET | by André Will-Laudien

Pfizer, GlaxoSmithKline, EXMceuticals - Research in competition

  • Health

By the end of 2020, the drug market is expected to more than double to USD 1.3 trillion, with the E7 countries - Brazil, China, India, Indonesia, Mexico, Russia and Turkey - accounting for about one-fifth of global drug sales. Also, the incidence of chronic diseases in developing countries will increasingly resemble that in industrialized countries. The evidence is abundant that the pharmaceutical industry business model is both economically unsustainable and operationally lethargic to produce the types of innovative treatments demanded by global markets. The industry must fundamentally change the way it operates to take full advantage of future growth opportunities. PwC's management consultants expect the industry to shift its focus from treatment to prevention. The traditional blockbuster sales model will disappear, and sophisticated direct sales channels will diminish the role of wholesalers. Let's take a closer look!

Read

29. September 2020 | 10:51 CET | by Mario Hose

BioNTech, Bayer, Valeo Pharma: Share price jump ahead of quarterly results

  • Health

Investors' expectations of developments can drive the share price. When it comes to solving a problem or creating needs, the interest of the capital market is particularly high. Things get exciting for investors when the business model offers the possibilities of scalability. Attractive investment opportunities can be created in the fields of health and medicine, which offer extraordinary return opportunities.

Read